A novel triazole nucleoside analogue was discovered to exhibit potent anticancer
activity in prostate cancer cells via down-regulating heat shock factor 1 (HSF1) and related heat
shock proteins, along with the consequential inhibition of androgen receptor (AR) expression
and transactivation, arresting the cell cycle in AR-governed phase. This triazole nucleoside
therefore constitutes a novel structural paradigm and potential drug candidate for prostate cancer
through inhibition of HSF1 and AR.
Keywords: Androgen receptor, anticancer activity, heat shock proteins, heat shock factor 1, nucleoside analogues, prostate cancer.
Rights & PermissionsPrintExport